Abbott has announced that both the XIENCE PRIME(TM)Everolimus Eluting Coronary Stent System(1) and the XIENCE V(R) Everolimus Eluting Coronary Stent System have received additional new CE Markings covering the treatment of patients with diabetes. Receiving these new indications among the European Union Member States validates the use of XIENCE PRIME and XIENCE V to treat patients with diabetes. Coronary artery disease is one of the most common cardiovascular complications of diabetes.

Research and Markets has announced the addition of the “Cord Blood Stem Cells – A Global Market Overview” report to their offering. Umbilical cord and placenta, once considered medical waste are emerged to be a valuable source of stem cells. The cord blood stem cells show the potential to treat the fatal diseases such as leukemia, cardiac attacks and debilitating diseases including Alzheimer’s and Parkinson’s.

Clear Catheter Systems has been awarded the 2009 EACTS Techno-College Innovation Award for its PleuraFlow Active Tube Clearance System. The Techno-College Award is a worldwide competition to identify innovations with the potential to change the standard of care in heart and lung surgery. The award was established by the European Association of Cardio-Thoracic Surgery to recognize the most important technological breakthrough related to thoracic and cardiovascular surgery.

DSM PTG, part of DSM Biomedical, has announced the availability of Bionate® II PCU, a versatile medical polymer with built-in surface technology designed for chronic implants. Bionate® II PCU is a line extension of the well known Bionate® Polycarbonate Urethane family, one of the industry’s leading medical polymers for long-term implants and is backed by an established FDA Master File. The new polymer offers improved performance and processing characteristics for medical devices.